These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1379 related articles for article (PubMed ID: 33171139)

  • 1. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
    Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
    Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9.
    Wang Y; Hao L; Wang H; Santostefano K; Thapa A; Cleary J; Li H; Guo X; Terada N; Ashizawa T; Xia G
    Mol Ther; 2018 Nov; 26(11):2617-2630. PubMed ID: 30274788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9-Induced (CTG⋅CAG)
    van Agtmaal EL; André LM; Willemse M; Cumming SA; van Kessel IDG; van den Broek WJAA; Gourdon G; Furling D; Mouly V; Monckton DG; Wansink DG; Wieringa B
    Mol Ther; 2017 Jan; 25(1):24-43. PubMed ID: 28129118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome Editing of Expanded CTG Repeats within the Human DMPK Gene Reduces Nuclear RNA Foci in the Muscle of DM1 Mice.
    Lo Scrudato M; Poulard K; Sourd C; Tomé S; Klein AF; Corre G; Huguet A; Furling D; Gourdon G; Buj-Bello A
    Mol Ther; 2019 Aug; 27(8):1372-1388. PubMed ID: 31253581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas Applications in Myotonic Dystrophy: Expanding Opportunities.
    Raaijmakers RHL; Ripken L; Ausems CRM; Wansink DG
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells.
    Dastidar S; Ardui S; Singh K; Majumdar D; Nair N; Fu Y; Reyon D; Samara E; Gerli MFM; Klein AF; De Schrijver W; Tipanee J; Seneca S; Tulalamba W; Wang H; Chai YC; In't Veld P; Furling D; Tedesco FS; Vermeesch JR; Joung JK; Chuah MK; VandenDriessche T
    Nucleic Acids Res; 2018 Sep; 46(16):8275-8298. PubMed ID: 29947794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
    Long C; Amoasii L; Bassel-Duby R; Olson EN
    JAMA Neurol; 2016 Nov; 73(11):1349-1355. PubMed ID: 27668807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
    El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
    Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive transcriptome-wide analysis of spliceopathy correction of myotonic dystrophy using CRISPR-Cas9 in iPSCs-derived cardiomyocytes.
    Dastidar S; Majumdar D; Tipanee J; Singh K; Klein AF; Furling D; Chuah MK; VandenDriessche T
    Mol Ther; 2022 Jan; 30(1):75-91. PubMed ID: 34371182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.
    Bengtsson NE; Hall JK; Odom GL; Phelps MP; Andrus CR; Hawkins RD; Hauschka SD; Chamberlain JR; Chamberlain JS
    Nat Commun; 2017 Feb; 8():14454. PubMed ID: 28195574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
    Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
    Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sustained expression of Cas9 targeting toxic RNAs reverses disease phenotypes in mouse models of myotonic dystrophy type 1.
    Batra R; Nelles DA; Roth DM; Krach F; Nutter CA; Tadokoro T; Thomas JD; Sznajder ŁJ; Blue SM; Gutierrez HL; Liu P; Aigner S; Platoshyn O; Miyanohara A; Marsala M; Swanson MS; Yeo GW
    Nat Biomed Eng; 2021 Feb; 5(2):157-168. PubMed ID: 32929188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-Cas9 in genome editing: Its function and medical applications.
    Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
    J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Cas9 Genome Editing in Human Cell Lines with Donor Vector Made by Gibson Assembly.
    Sahoo N; Cuello V; Udawant S; Litif C; Mustard JA; Keniry M
    Methods Mol Biol; 2020; 2115():365-383. PubMed ID: 32006411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impeding Transcription of Expanded Microsatellite Repeats by Deactivated Cas9.
    Pinto BS; Saxena T; Oliveira R; Méndez-Gómez HR; Cleary JD; Denes LT; McConnell O; Arboleda J; Xia G; Swanson MS; Wang ET
    Mol Cell; 2017 Nov; 68(3):479-490.e5. PubMed ID: 29056323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
    Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
    Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9.
    Li A; Tanner MR; Lee CM; Hurley AE; De Giorgi M; Jarrett KE; Davis TH; Doerfler AM; Bao G; Beeton C; Lagor WR
    Mol Ther; 2020 Jun; 28(6):1432-1441. PubMed ID: 32348718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing.
    Edraki A; Mir A; Ibraheim R; Gainetdinov I; Yoon Y; Song CQ; Cao Y; Gallant J; Xue W; Rivera-Pérez JA; Sontheimer EJ
    Mol Cell; 2019 Feb; 73(4):714-726.e4. PubMed ID: 30581144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward In Vivo Gene Therapy Using CRISPR.
    Skipper KA; Mikkelsen JG
    Methods Mol Biol; 2019; 1961():293-306. PubMed ID: 30912053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.